Chronic hepatitis B: Advances in treatment

被引:10
作者
Teresa Antonia Santantonio [1 ]
Massimo Fasano [1 ]
机构
[1] Department of Clinical and Experimental Medicine, University of Foggia, 71100 Foggia, Italy
关键词
Chronic hepatitis; Antiviral therapy; Peginterferon; Nucleos(t)ide analogues; Antiviral resistance;
D O I
暂无
中图分类号
R512.62 [];
学科分类号
100401 ;
摘要
Treatment of chronic hepatitis B(CHB) has markedly improved in the last 15 years due to the availability of direct antivirals which greatly increase therapeutic options. Currently, there are two classes of agents licensed for CHB treatment: standard or pegylated interferon alpha(IFN or Peg-IFN) and five nucleoside/nucleotide analogues(NAs). Long-term treatment with NAs is the treatment option most often used in the majority of CHB patients. Entecavir and tenofovir, the most potent NAs with high barrier to resistance, are recommended as first-line monotherapy by all major treatment guidelines and can lead to long-lasting viro-logical suppression, resulting in histological improve-ment or reversal of advanced fibrosis and reduction in disease progression and liver-related complications. In this review, we focus on current treatment strategies of chronic hepatitis B and discuss the most recent efficacy and safety data from clinical trials and real life clinical practice. Recent findings of response-guided approach-es are also discussed.
引用
收藏
页码:284 / 292
页数:9
相关论文
共 26 条
  • [1] No Detectable Resistance to Tenofovir Disoproxil Fumarate After 6 Years of Therapy in Patients With Chronic Hepatitis B
    Kitrinos, Kathryn M.
    Corsa, Amoreena
    Liu, Yang
    Flaherty, John
    Snow-Lampart, Andrea
    Marcellin, Patrick
    Borroto-Esoda, Katyna
    Miller, Michael D.
    [J]. HEPATOLOGY, 2014, 59 (02) : 434 - 442
  • [2] 755 5-YEAR ENTECAVIR TREATMENT IN NUC-NA?VE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS[J] . P. Lampertico,R. Soffredini,M. Viganò,E. Minola,G. Cologni,M. Rizzi,S. Zaltron,A. Vavassori,F. Castelli,E. Angeli,G.A. Gubertini,C. Magni,G. Rizzardini,A. Testa,G. D’Offizi,M. Vinci,G. Pinzello,E. Fatta,S. Fargion,S. Colombo,O. Fracassetti,P. Del Poggio,B. Coco,M.R. Brunetto,M. Andreoletti,A. Colli,M. Fasan
  • [3] 772 SERUM HEPATITIS B SURFACE ANTIGEN LEVELS DURING FIVE YEARS ENTECAVIR THERAPY IN ASIAN CHRONIC HEPATITIS B PATIENTS[J] . W.-K. Seto,Y.-F. Lam,J. Fung,D.K.-H. Wong,C.-L. Lai,M.-F. Yuen.Journal of Hepatology . 2013
  • [4] EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J] . European Association for the Study of the Liver.Journal of Hepatology . 2012 (1)
  • [5] Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J] . Patrick Marcellin,Edward Gane,Maria Buti,Nezam Afdhal,William Sievert,Ira M Jacobson,Mary Kay Washington,George Germanidis,John F Flaherty,Raul Aguilar Schall,Jeffrey D Bornstein,Kathryn M Kitrinos,G Mani Subramanian,John G McHutchison,E Jenny Heathcote.The Lancet . 2012
  • [6] Management of treatment failure in chronic hepatitis B[J] . Fabien Zoulim,Stephen Locarnini.Journal of Hepatology . 2012
  • [7] Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
    Rijckborst, Vincent
    Hansen, Bettina E.
    Ferenci, Peter
    Brunetto, Maurizia R.
    Tabak, Fehmi
    Cakaloglu, Yilmaz
    Lanza, A. Galeota
    Messina, Vincenzo
    Iannacone, Claudio
    Massetto, Benedetta
    Regep, Loredana
    Colombo, Massimo
    Janssen, Harry L. A.
    Lampertico, Pietro
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (05) : 1006 - 1011
  • [8] Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients
    Buti, Maria
    Maria Morillas, Rosa
    Prieto, Martin
    Diago, Moises
    Perez, Juan
    Sola, Ricard
    Bonet, Lucia
    Palau, Antonio
    Testillano, Milagros
    Garcia-Samaniego, Javier
    Rodriguez, Manuel
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (05) : 535 - 542
  • [9] Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
    Sonneveld, Milan J.
    Rijckborst, Vincent
    Zeuzem, Stefan
    Heathcote, E. Jenny
    Simon, Krzysztof
    Senturk, Hakan
    Pas, Suzan D.
    Hansen, Bettina E.
    Janssen, Harry L. A.
    [J]. HEPATOLOGY, 2012, 56 (01) : 67 - 75
  • [10] Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B
    Sonneveld, Milan J.
    Wong, Vincent W-S.
    Woltman, Andrea M.
    Wong, Grace L. H.
    Cakaloglu, Yilmaz
    Zeuzem, Stefan
    Buster, Erik H. C. J.
    Uitterlinden, Andre G.
    Hansen, Bettina E.
    Chan, Henry L. Y.
    Janssen, Harry L. A.
    [J]. GASTROENTEROLOGY, 2012, 142 (03) : 513 - U165